GNH USA

Europe — EMA

Icatibant Synchrony Pharma

GNH USA supplies Icatibant Synchrony Pharma (Icatibant), a bradykinin B2 receptor antagonist for acute hereditary angioedema attacks.

Icatibant

Request sourcing

1
Pack/s

What is Icatibant?

Icatibant, the active ingredient in Icatibant Synchrony Pharma, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It is indicated for the treatment of acute hereditary angioedema attacks in patients with C1‑inhibitor deficiency, helping to reduce swelling of the skin, gastrointestinal tract, and upper airway.

GNH USA supplies Icatibant Synchrony Pharma as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide through regulated distribution channels that meet European Union quality standards.

What is Icatibant used for?

Icatibant is used to treat conditions mediated by excessive bradykinin activity, primarily hereditary angioedema. - Hereditary angioedema (HAE) with C1‑inhibitor deficiency: rapid relief of acute swelling episodes - Cutaneous HAE attacks (skin swelling): reduces edema and associated pain - Abdominal HAE attacks (gastrointestinal edema): alleviates abdominal pain and distension - Laryngeal HAE attacks (airway swelling): helps prevent airway obstruction

What are the side effects of Icatibant?

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site - Redness or erythema: localized skin reddening - Swelling at injection site: transient edema - Nausea: occasional gastrointestinal upset - Headache: mild to moderate intensity - Dizziness: transient light‑headedness

Serious or Rare Side Effects: - Hypersensitivity reaction: rash, urticaria, or anaphylaxis - Severe hypotension: marked drop in blood pressure - Paradoxical angioedema: worsening swelling despite therapy - Thrombocytopenia: reduced platelet count - Infection at injection site: cellulitis or abscess formation

What precautions apply to Icatibant?

Before using Icatibant, consider the following safety measures. - Pregnancy: safety not established; use only if potential benefit justifies the risk - Breastfeeding: unknown excretion; evaluate risk versus benefit - Renal impairment: no specific dose adjustment, but monitor renal function - Concomitant ACE inhibitors or ARBs: increased bradykinin may raise angioedema risk; monitor closely - Hypersensitivity: discontinue immediately if severe allergic reaction occurs - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

What does Icatibant interact with?

Icatibant can interact with other medicines that affect bradykinin pathways or blood pressure.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may increase angioedema risk - Angiotensin receptor blockers (ARBs): similar risk of enhanced bradykinin activity - Other bradykinin B2 receptor antagonists: may reduce therapeutic efficacy

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effects of icatibant - Antihistamines: could mask early signs of hypersensitivity reactions

Frequently asked questions

What is Icatibant Synchrony Pharma used for?+
Icatibant Synchrony Pharma is used to treat acute attacks of hereditary angioedema (HAE) in patients who have a deficiency of C1‑inhibitor. By blocking the bradykinin B2 receptor, it helps to quickly reduce swelling of the skin, gastrointestinal tract, and airway that can occur during an HAE episode.
How does icatibant work in the body?+
Icatibant works as a selective competitive antagonist of the bradykinin B2 receptor. By occupying this receptor on vascular endothelial cells, it prevents bradykinin from triggering vasodilation and increased vascular permeability, which are the primary mechanisms behind the swelling seen in hereditary angioedema.
What is the usual dose of icatibant?+
The dose of icatibant is determined by the prescribing healthcare professional based on the patient’s clinical condition and regulatory guidelines. The medication is administered as a subcutaneous injection, and the prescriber will specify the exact amount and frequency required for each acute HAE episode.
Is icatibant safe to use during pregnancy or breastfeeding?+
Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will assess individual circumstances before prescribing.
How do I order Icatibant Synchrony Pharma from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, indicating the required quantity. GNH USA supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.
How does icatibant compare with other hereditary angioedema treatments?+
Icatibant is a bradykinin B2 receptor antagonist, whereas other HAE therapies such as C1‑inhibitor concentrates replace the deficient protein, and monoclonal antibodies target different pathways. Icatibant provides rapid symptom relief through direct receptor blockade, making it useful for patients who prefer subcutaneous self‑administration or when protein‑based products are unavailable.
What are the storage and handling requirements for icatibant?+
Icatibant solution for injection should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period, then return to refrigeration as soon as possible.
How is icatibant administered?+
Icatibant is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after appropriate instruction, by the patient or caregiver. The site should be rotated for each dose, and aseptic technique must be followed to minimize infection risk.
What are the most serious risks associated with icatibant?+
The most serious risks include severe hypersensitivity reactions such as anaphylaxis, marked hypotension, and paradoxical worsening of angioedema despite treatment. Patients should be monitored closely after injection, and any signs of severe allergic reaction or sudden blood pressure drop require immediate medical attention.
Who should not use icatibant?+
Icatibant should be avoided in individuals with known hypersensitivity to icatibant or any of its excipients. Patients taking ACE inhibitors or ARBs should use it only under close medical supervision due to an increased risk of angioedema. It is also contraindicated in patients with severe uncontrolled hypotension.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Icatibant
Route
Subcutaneous Use
Manufacturer
Synchrony Pharma Limited
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU